Advertisement
Screener

BioNexus Gene Lab Corp. (BGLC) Graph

BGLC Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $76.16K; Revenue including tax $76.16K; Cost of revenue $63.17K; Research and development $13.67K.
  • 2026-03-31: Revenue $22.84K; Revenue including tax (m); Cost of revenue $23.63K; Research and development $14.49K.
  • 2025-12-31: Revenue $483.76K*; Revenue including tax (m); Cost of revenue $487.74K*; Research and development $11.10K*.
  • 2025-09-30: Revenue $2.54M; Revenue including tax (m); Cost of revenue $2.17M; Research and development $14.88K.

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

BGLC revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.BD$0.00ID$0.00LK$0.00MM$63.72KMV$0.00SG$0.00ZA$12.44KRevenue$76.16KCost of revenue$63.17KGross profit$12.98KOperating expenses$416.38KOperating income-$282.40KResearch & development$13.67KPre-tax income-$286.45KIncome tax$0.00Net income-$286.45K

Timing Of Transfer Of Good Or Service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

BGLC revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Screening ServicesAnd Related Sales$650.00Trading OfIndustrial Chemicals$75.51KRevenue$76.16KCost of revenue$63.17KGross profit$12.98KOperating expenses$416.38KOperating income-$282.40KResearch & development$13.67KPre-tax income-$286.45KIncome tax$0.00Net income-$286.45K

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$76.16K$76.16K$63.17K$13.67K$416.38K$0.00-$286.45K
2026-03-31$22.84K(m)$23.63K$14.49K$597.39K$0.00-$543.58K
2025-12-31$483.76K*(m)$487.74K*$11.10K*$1.05M*$0.00*-$1.04M*
2025-09-30$2.54M(m)$2.17M$14.88K$1.19M$0.00-$708.99K
2025-06-30$2.26M$2.26M$1.89M$12.56K$1.19M$0.00-$616.17K
2025-03-31$2.14M(m)$1.79M$12.14K$1.05M$0.00-$623.33K
2024-09-30$2.63M(m)$2.30M$10.44K$2.13M$1.55K-$1.35M
2024-06-30$1.97M(m)$1.69M$8.20K$759.66K$55.58K$199.10K
2024-03-31$2.38M(m)$2.02M$11.47K-$645.91K-$20.07K-$103.76K
2023-09-30$2.55M(m)$2.20M(m)(m)$76.42K-$2.61M
2023-06-30$2.57M(m)$2.23M(m)(m)$15.99K-$259.25K
2023-03-31$2.38M(m)$2.01M(m)(m)-$15.99K-$69.07K
2022-09-30$2.58M(m)$2.28M(m)(m)$10.11K-$77.40K
2022-06-30$2.49M(m)$2.22M(m)(m)-$1.62K-$138.66K
2022-03-31$3.03M(m)$2.67M(m)(m)$14.30K$17.07K
2021-09-30$3.58M(m)$2.87M(m)(m)$75.17K$295.32K
2021-06-30$3.09M(m)$2.62M(m)(m)$108.28K$28.26K
2021-03-31$3.45M(m)$2.87M(m)(m)$0.00$338.74K
2020-09-30$3.09M(m)$2.57M(m)(m)-$492.00$234.46K
2020-06-30$1.10M(m)$944.23K(m)(m)$487.00-$35.84K
2020-03-31$3.07M(m)$2.41M(m)(m)$860.00$1.07M
2019-09-30$24.17K(m)$16.50K(m)(m)$28.11K-$22.03K
2019-06-30$21.64K(m)$17.02K(m)(m)$1.18K-$70.40K
2019-03-31$28.09K(m)-$18.82K(m)(m)-$1.26K-$61.47K
2018-09-30$91.63K(m)-$69.25K(m)(m)(m)-$88.96K
2018-06-30$111.30K(m)$85.65K(m)(m)$0.00-$39.47K
2018-03-31(m)(m)-$12.53K(m)(m)(m)$271.86K

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$99.00K$99.00K$86.81K$28.16K$1.01M$0.00-$830.03K
2025-06-30$4.40M$4.40M$3.69M$24.70K$2.24M$0.00-$1.24M
2024-06-30$4.36M(m)$3.70M$19.67K$1.41M$75.65K$95.35K
2023-06-30$4.94M(m)$4.24M(m)(m)$0.00-$328.32K
2022-06-30$5.51M(m)$4.89M(m)(m)$12.68K-$121.60K
2021-06-30$6.54M(m)$5.49M(m)(m)$108.28K$367.01K
2020-06-30$4.17M(m)$3.36M(m)(m)$1.35K$1.03M
2019-06-30$49.73K(m)$35.84K(m)(m)$2.44K-$131.87K
2018-06-30$111.30K(m)$98.18K(m)(m)$0.00$178.39K

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$6.94M$5.85M$39.57K$3.43M$0.00-$1.95M
2024-09-30$6.99M$6.01M$30.11K$3.54M$77.21K-$1.25M
2023-09-30$7.50M$6.43M(m)(m)$76.42K-$2.94M
2022-09-30$8.09M$7.17M(m)(m)$22.79K-$199.00K
2021-09-30$10.12M$8.33M(m)(m)$183.45K$662.33K
2020-09-30$7.26M$5.93M(m)(m)-$1.84K$1.27M
2019-09-30$73.91K$52.34K(m)(m)$25.67K-$153.89K
2018-09-30$202.92K-$167.43K(m)(m)-$33.82K$89.43K

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$7.42M$6.34M$50.67K$4.48M$0.00-$2.98M
2024-12-31$9.51M$8.22M$47.51K$4.94M-$3.49K-$1.60M
2023-12-31$9.77M$8.44M$54.98K-$4.41M-$21.53K-$2.63M
2022-12-31$10.93M$9.67M(m)(m)-$52.31K-$355.97K
2021-12-31$13.36M$11.10M(m)(m)-$291.28K$751.57K
2020-12-31$11.39M$9.67M(m)(m)(m)$1.09M
2019-12-31$126.95K$71.07K(m)(m)$24.76K-$246.47K
2018-12-31$212.33K-$183.56K(m)(m)-$33.45K$26.45K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclarion, Inc. (ACON)United States$0.008B
Advanced Biomed Inc. (ADVB)$0.009B
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45